Tag - CATB

Markets

Ladenburg starts Catabasis Pharma at buy; PT $6

Ladenburg Thalmann launched coverage of Catabasis Pharmaceuticals (NASDAQ:CATB) with a “buy” rating and price target of $8. The stock closed at $1.78 on May 11. Catabasis is a Boston-based biotechnology company focused...

May 12, 2021

Markets

HCW cuts Catabasis Pharma to neutral; removes PT

H.C. Wainwright downgraded Catabasis Pharmaceuticals (NASDAQ:CATB) to “neutral” from “buy” and removed its price target after the company announced that the Phase 3 PolarisDMD trial testing edasalonexent in 131 patients...

October 27, 2020

Markets

HCW starts Catabasis Pharma at buy; PT $24

H.C. Wainwright launched coverage of Catabasis Pharmaceuticals (NASDAQ:CATB) with a “buy” rating and $24 price target. The stock closed at $6.19 on Sept. 30. Catabasis is developing edasalonexent, an oral small molecule...

October 1, 2020

Developments

Catabasis Pharma exceeds target enrollment for global Phase 3 DMD trial

Catabasis Pharmaceuticals (NASDAQ:CATB) completed enrollment for its Phase 3 trial of edasalonexent for the treatment Duchenne muscular dystrophy (DMD). Taking place at 40 clinical sites in eight countries, the trial...

October 1, 2019

Executive Moves

Catabasis Pharma names Andrew Komjathy as chief commercial officer

Andrew Komjathy Catabasis Pharmaceuticals (NASDAQ:CATB) appointed Andrew Komjathy as its chief commercial officer. Catabasis’ lead program is edasalonexent for the treatment of Duchenne muscular dystrophy (DMD). The...

September 25, 2019

Tag - CATB

Ladenburg starts Catabasis Pharma at buy; PT $6

HCW cuts Catabasis Pharma to neutral; removes PT

HCW starts Catabasis Pharma at buy; PT $24

Catabasis Pharma exceeds target enrollment for global Phase 3 DMD trial

Catabasis Pharma names Andrew Komjathy as chief commercial officer

General

More